Astellas Pharma Inc.: Approval for Supplemental New Drug Application for the Selective COX-2 Inhibitor Celecox® Tablet in Japan Tokyo, December 22, [removed]Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and - Crime in Japan - Document - PDFSEARCH.IO

First Page	Meta Content
	Astellas Pharma Inc.: Approval for Supplemental New Drug Application for the Selective COX-2 Inhibitor Celecox® Tablet in Japan Tokyo, December 22, [removed]Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and Add to Reading List Document Date: 2011-12-21 20:54:23 Open Document File Size: 30,35 KB Share Result on Facebook City Tokyo / / Company Pfizer Japan Inc. / Pfizer Inc. / COX / Astellas Pharma Inc. / / Country Japan / United States / / Event FDA Phase / / / IndustryTerm finished products / active pharmaceutical ingredient / chemicals / / MedicalCondition osteoarthritis / scapulohumeral periarthritis / pain / cervico-omo-brachial syndrome / lumbago / rheumatoid arthritis / inflammation / / Person Yoshihiko Hatanaka / Ichiro Umeda / / / Position President / President and CEO / / Product COX-2 / / URL http / SocialTag Pharmacology Corporate crime Dow Jones Industrial Average Pfizer Celecoxib Astellas Pharma Pharmaceutical drug Paracetamol COX-2 inhibitor Non-steroidal anti-inflammatory drugs

Astellas Pharma Inc.: Approval for Supplemental New Drug Application for the Selective COX-2 Inhibitor Celecox® Tablet in Japan Tokyo, December 22, [removed]Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and Add to Reading List